Alentis Therapeutics is a biotech company focused on developing treatments for cancer and reversing fibrosis by targeting Claudin-1, a protein involved in disease signaling and tumor cell growth.

Neil Goldsmith

Thomas Baumert

Alentis Therapeutics

Campus Biotech is an interdisciplinary center dedicated to neuroscience and digital and global health. It aims to transform innovation into medical advancements.

Campus Biotech

Switzerland Innovation Park Basel Area provides ready-made and customizable workspaces for various teams, focusing on innovation in healthcare, life sciences, and technology.

Switzerland Innovation Park Basel Area

Alentis Therapeutics, the Claudin-1 (CLDN1) company, is a clinical stage biotechnology company on a mission to develop first-in-class antibodies and ADCs for CLDN1+ tumors and organ fibrosis. 

Alentis is pioneering a novel approach to modify and reverse the course of disease progression targeting CLDN1, a previously unexploited target that plays a key role in the pathology of tumors and fibrotic diseases across multiple organs. Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting CLDN1. 

Alentis’ portfolio of anti-CLDN1 monoclonal antibodies includes a novel class of anti-cancer therapies designed to reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is highly promising for drug development as many cancers use the TME to build barriers that shield against immune system attacks. Alentis’ lead oncology asset, ALE.C04, is the first potential treatment to target CLDN1 in solid tumors.

In addition, Alentis’ pipeline includes first-in-class therapies designed to modify and reverse the course of advanced organ fibrosis. ALE.F02, which is currently in Phase 1 clinical trials, is designed to target pathological overexpression of CLDN1 outside of the tight junction to resolve and reverse organ fibrosis and is being investigated for the treatment of fibrotic disease in the kidney, lung, and liver. 

The company was founded in 2019 based on ground-breaking research in the laboratory of Prof. Thomas Baumert MD at the University of Strasbourg and the French National Institute of Health (Inserm). 

Alentis is headquartered in Basel’s pharma-biotech hub in Switzerland with a subsidiary for R&D in Strasbourg, France. For more information, please visit us at www.alentis.ch or write to: info@alentis.ch

Metric
Company Name	Alentis Therapeutics	Campus Biotech	Switzerland Innovation Park Basel Area
Symbol
MSH ID	CH:ALENTIS	CH:CAMPUSBIOTECH	COM:SIP-BASELAREA
Market	PRIVATE	PRIVATE	PRIVATE
Sector	Commercial & Professional Services	Healthcare & Health Services	Commercial & Professional Services
Industry	Biotechnology	Life Sciences	Real Estate
Country	CH	CH	CH
Stage	Series D
Employee Count	59
Website	alentis.ch	campusbiotech.ch	sip-baselarea.com
LinkedIn	alentis-therapeutics	campus-biotech	switzerland-innovation-park-basel-area
Founders

Metric
Market Cap	731.80M
Enterprise Value
Monthly Web Traffic	913	6.83K
Web Traffic Growth	-0.55	-0.59
Valuation
Raised Capital	181.40M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CH:ALENTIS

Alentis Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue